Comparison of BCR-ABL Transcript Variants Between Patients With Chronic Myeloid Leukaemia and Leukaemia Cell Lines

被引:4
|
作者
Sales, Livia De Oliveira [1 ]
Mesquita, Felipe Pantoja [2 ]
De Sousa Portilho, Adrhyann Jullyanne [2 ]
De Moraes Filho, Manoel Odorico [2 ]
Amaral De Moraes, Maria Elisabete [2 ]
Montenegro, Raquel Carvalho [2 ]
Moreira-Nunes, Caroline Aquino [1 ,2 ]
机构
[1] Christus Univ Ctr Unichristus, Fac Biomed, Fortaleza, Ceara, Brazil
[2] Univ Fed Ceara, Drug Res & Dev Ctr NPDM, Dept Physiol & Pharmacol, Pharmacogenet Lab, Fortaleza, Ceara, Brazil
来源
IN VIVO | 2019年 / 33卷 / 04期
关键词
CML; leukaemia; BCR-ABL; cell lines; MULTIDRUG-RESISTANCE; IMATINIB MESYLATE; MOLECULAR-BIOLOGY; CML; EXPRESSION; E13A2;
D O I
10.21873/invivo.11581
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background/aim: Chronic myeloid leukaemia (CML) is a myeloproliferative disorder characterized by the presence of breakpoint cluster region-Abelson murine leukemia (BCR-ABL1) gene fusion as a hallmark that is expressed as two major transcripts b2a2 and b3a2. The aim of this study was to compare the BCR-ABL transcripts in the blood cells of patients with CML, and in chemoresistant and chemosensitive CML cell lines to validate their use as a good method to elucidate CML biology. Materials and Methods: Twelve patients with CML and CML cell lines (K562, K562-LUCENA and FEPS) were analyzed by real-time polymerase chain reaction to evaluate gene expression of BCR-ABL transcripts. Results: All patients had the same expression levels of b2a2 and b3a3 transcripts, however, CML cell lines presented only b3a2 expression. There were no significant differences in absolute b3a2 expression between patients and CML cell lines. Conclusion: CML cell lines provide a good in vitro alternative in that they have the same BCR-ABL expression as patients.
引用
收藏
页码:1119 / 1124
页数:6
相关论文
共 50 条
  • [41] Cross-talk between Bcr-abl and the Thioredoxin System in Chronic Myeloid Leukaemia: Implications for CML Treatment
    Clapper, Erin
    Wang, Sicong
    Raninga, Prahlad V.
    Di Trapani, Giovanna
    Tonissen, Kathryn F.
    ANTIOXIDANTS, 2020, 9 (03)
  • [42] Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study
    Rojas, J. M.
    Knight, K.
    Wang, L.
    Clark, R. E.
    LEUKEMIA, 2007, 21 (11) : 2287 - 2295
  • [43] Characteristics of BCR-ABL gene variants in patients of chronic myeloid leukemia
    Amin, Huma
    Ahmed, Suhaib
    OPEN MEDICINE, 2021, 16 (01): : 904 - 912
  • [45] Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia
    Weisberg, Ellen
    Manley, Paul W.
    Cowan-Jacob, Sandra W.
    Hochhaus, Andreas
    Griffin, James D.
    NATURE REVIEWS CANCER, 2007, 7 (05) : 345 - U5
  • [46] Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study
    J M Rojas
    K Knight
    L Wang
    R E Clark
    Leukemia, 2007, 21 : 2287 - 2295
  • [47] Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia
    Ellen Weisberg
    Paul W. Manley
    Sandra W. Cowan-Jacob
    Andreas Hochhaus
    James D. Griffin
    Nature Reviews Cancer, 2007, 7 : 345 - 356
  • [48] One-tube multiplex RT-PCR of BCR-ABL transcripts in analysis of patients with chronic myeloid leukaemia and acute lymphoblastic leukaemia
    Nogva, HK
    Evensen, SA
    Madshus, IH
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 1998, 58 (08): : 647 - 654
  • [49] Clinical BCR-ABL peptide vaccination in chronic myeloid leukaemia: Results of the EPIC study.
    Rojas, Jose M.
    Knight, Katy
    Wang, Li-Hui
    Clark, Richard E.
    BLOOD, 2006, 108 (11) : 623A - 623A
  • [50] Is Bcr-Abl expression relevant for the survival of cancer stem cells in chronic myeloid leukaemia (CML)?
    Helgason, G. V.
    Hamilton, A.
    Myssina, S.
    Jorgensen, H. G.
    Bhatia, R.
    Modi, H.
    Schemionek, M.
    Koschmieder, S.
    Brunton, V.
    Holyoake, T. L.
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 149 : 72 - 72